Evaluating the Safety and Efficacy of Ticagrelor vs. Clopidogrel Following Percutaneous Coronary Intervention in Chronic Coronary Disease.

Objective This study aimed to compare the safety and efficacy of ticagrelor and clopidogrel in reducing major adverse cardiovascular events (MACE) among patients undergoing percutaneous coronary intervention (PCI) for chronic coronary disease. Additionally, secondary endpoints, including adverse events such as major bleeding, minor bleeding, and dyspnea, were assessed to evaluate the overall safety profile of both antiplatelet therapies. Methodology A prospective cohort study was conducted at Kuwait Teaching Hospital, Peshawar, Pakistan, enrolling 300 patients (150 receiving ticagrelor and 150 receiving clopidogrel) from July 2023 to June 2024.